The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC).
 
Aaron Michael Laine
Research Funding - Celgene (Inst)
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Research Funding - ArQule (Inst); BerGenBio (Inst); Celgene (Inst); Genentech (Inst); ImClone Systems (Inst); Immunogen (Inst); Synta (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Lilly; Lilly
 
Puneeth Iyengar
Consulting or Advisory Role - Helsinn Therapeutics
 
Kenneth Westover
Research Funding - Astellas Pharma (Inst)
 
Irma Smith
No Relationships to Disclose
 
Yuhchyau Chen
No Relationships to Disclose
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Mark A. Socinski
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Research Funding - Pfizer (Inst)
 
Hak Choy
Research Funding - Celgene